The agenda for the September 2026 Pharmaceutical Benefits Advisory Committee (PBAC) meeting is now available. Information about each item can also be found on the Medicine Status Website (from 1 September 2026).
Consultation is open for Zoladex® 10.8 mg Implant (goserelin) for the proposed treatment of hormone receptor-positive breast cancer. The consultation period is shorter than usual to enable input to be considered at the September 2026 PBAC meeting.
Your comments are welcome whether you are a patient, carer, member of the public, health professional or member of a consumer interest group. The company applying for subsidy under the Pharmaceutical Benefits Scheme has already provided the PBAC with detailed clinical and economic data in support of the application. You are welcome to provide comments, for consideration by the PBAC, from a personal or group perspective on the impact of the condition addressed in the application. Further information about the PBAC process and how to provide input can be found on the Office of Health Technology Assessment (OHTA) Consultation Hub.